INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger - RRC, SGRY, BOLT and PCRX - IS IT A FAIR DEAL FOR YOU?

Monteverde & Associates said it is investigating the fairness of four proposed transactions: Range Resources’ merger with EQT, Surgery Partners’ $23.50-per-share cash sale to HealthSpan Partners, Bolt Biotherapeutics’ merger with Prana Therapies, and Pacira BioSciences’ $36.50-per-share cash sale to Viatris. Range shareholders are expected to receive 0.987 EQT shares per Range share; the firm did not state that any transaction was unfair or provide findings.

Analysis

This is an attorney solicitation, not evidence that a complaint has been filed, that a regulator has intervened, or that any transaction is unfair. The signal is therefore procedural: added headline noise may widen deal spreads briefly, but it does not by itself change transaction value or closing probability. The key near-term checks are definitive merger agreements, shareholder-vote and regulatory timelines, any actual court filing, and whether a court grants expedited relief. A filing could create delay and hedging costs; absent an injunction or credible deal challenge, a material change in expected consideration is not established here.

For Range Resources/EQT, the stated stock consideration makes the relevant exposure the RRC-to-EQT exchange ratio and EQT price through closing; a merger-arbitrage position requires sizing the EQT hedge to the contractual ratio and monitoring any deal protections or termination provisions. For the cash transactions involving Surgery Partners and Pacira BioSciences, the principal arb risks are time-to-close, financing/approval conditions, and break price—not the solicitation itself. Viatris may face capital-allocation or financing scrutiny if Pacira closes, but the release supplies no funding terms to underwrite that exposure. Bolt Biotherapeutics is least actionable: consideration and key terms are absent, so neither deal value nor an arb spread can be assessed.

Contrarian read: investors may overreact to the word “investigation,” while underweighting genuine execution risk if litigation actually seeks to delay a vote or closing. No directional equity trade is justified on this release alone; focus on deal spreads and verified docket developments.

Key Decisions for Investors

• No trade on the advertisement alone. Verify whether any complaint has actually been filed and whether it seeks injunctive relief; distinguish solicitation from litigation or a court order.
• If trading RRC/EQT, model the 0.987 exchange ratio and hedge EQT exposure accordingly; enter only if the observed spread compensates for expected time-to-close and break risk. Reassess on a filed challenge, vote delay, or amended transaction terms.
• For SGRY and PCRX, monitor deal spreads against cash consideration and confirm approval, financing, and termination conditions from definitive filings before considering spread capture; do not infer funding risk for Viatris without transaction financing details.
• Keep BOLT on watch rather than trade: obtain the merger agreement, consideration, and closing conditions first. Across all deals, widen required return or reduce exposure if a court grants expedited proceedings or an injunction; otherwise treat routine investigation headlines as low-information noise.